Regenxbio RGNX Cost Of License And Royalty Revenues
Cost Of License And Royalty Revenues at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:CostOfLicenseAndRoyaltyRevenues.
The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's cost of license and royalty revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's cost of license and royalty revenues?
- Regenxbio (RGNX) reported cost of license and royalty revenues of $11.07M in Q1 2026.
- How has Regenxbio's cost of license and royalty revenues changed year-over-year?
- Regenxbio's cost of license and royalty revenues increased by 222.3% year-over-year, from $3.44M to $11.07M.
- What does cost of license and royalty revenues mean?
- This metric represents the direct costs incurred to generate revenue from licensing intellectual property and royalty agreements. It typically includes payments to third-party licensors, sub-licensing fees, and other costs directly attributable to the maintenance and monetization of the company's patent portfolio. Monitoring this helps evaluate the profitability of the company's licensing business model.